Amgen (AMGN)

Competitors to Amgen (AMGN)

AbbVie 

AbbVie and Amgen compete primarily in the biologics space, focusing on treatments for autoimmune diseases and cancer. AbbVie’s strong portfolio includes its blockbuster drug Humira, which faces biosimilar competition but still generates significant revenue. Both companies invest heavily in research and development in therapeutic areas such as oncology and immunology, leading to innovation and competitive drug pipelines. However, Amgen has a diverse lineup of biologics and an established presence in other therapeutic areas like cardiovascular and bone health, giving it a competitive edge in portfolio diversity.

Bristol-Myers Squibb 

Bristol-Myers Squibb (BMS) and Amgen are both leaders in the biopharmaceutical sector, particularly in oncology and immunology. BMS’s portfolio includes strong oncology drugs like Opdivo and Yervoy, which position it well against Amgen’s cancer therapeutics. Both companies are engaged in extensive clinical trials and have robust drug pipelines, often showcasing new therapies at industry conferences. Amgen's strong emphasis on biologics, particularly in areas like bone health and cardiovascular disease, gives it a competitive edge in these specific areas, while BMS's robust oncology pipeline positions it as a formidable player in cancer treatment. The competition remains fierce, with both companies vying for leadership in different therapeutic domains.

Gilead Sciences 

Gilead Sciences and Amgen compete in the biotechnology sector with a focus on developing innovative therapeutic solutions for serious health conditions, including infectious diseases and cancer. Gilead is recognized for its antiviral therapies and has made significant inroads in cancer treatments as well. Both companies heavily invest in R&D and aim to expand their therapeutic portfolios. However, Amgen's expertise in biologics and diverse drug offerings provide it with a competitive advantage in specified therapeutic areas, while Gilead's stronghold on antiviral markets keeps it potent in another niche, creating a unique but competitive synergy.

Regeneron Pharmaceuticals 

Regeneron and Amgen are key players in the biotechnology field, with a focus on biopharmaceutical products for various diseases including cancer and eye conditions. Regeneron is well-known for its monoclonal antibody products like Eylea, which treats retinal diseases, and Dupixent, an asthma and eczema treatment. Both companies are engaged in extensive clinical trials and partnerships for future drug development. Amgen's strengths lie in its robust pipeline and breadth of product offerings, but Regeneron's strong innovation and high success rates in monoclonal antibody development position it as a fierce competitor. The competitive landscape can be considered balanced, but Regeneron benefits from its recent successful launches.

Sanofi 

Sanofi and Amgen compete in various therapeutic categories, including diabetes, oncology, and immunology, offering products that address similar disease states. Sanofi has a strong portfolio of vaccines and diabetes treatments that complement its presence in the biopharmaceutical market. Both companies innovate through large-scale clinical trials and partnerships. However, Amgen's competitive advantage lies in its established portfolio of biologics that target specific chronic conditions, combined with its innovative pipeline that is more focused on biologics compared to Sanofi's broader pharmaceutical offerings. Overall, while both companies are strong competitors, Amgen's niche capabilities provide it a competitive edge in biologics.